Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Results reported from pediatric Amoxicillin PULSYS phase III trial
August 26th, 2005
Advancis Pharmaceutical Corporation (AVNC) announced that the company's Amoxicillin PULSYS phase III clinical trial for the treatment of children with pharyngitis/tonsillitis due to Group A streptococcal infections (commonly referred to as strep throat) failed to achieve its desired microbiological and clinical endpoints. The trial compared Advancis' Amoxicillin PULSYS 775 milligram or 475 milligram "sprinkle" dosed once-daily for 7 days to an oral suspension of 10 milligrams per kilogram of penicillin VK dosed four times daily for 10 days. According to top-line trial data received today, Amoxicillin PULSYS failed to demonstrate statistical...
Source: Drug Week (2005-08-26)
|
